The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes
Abstract
BACKGROUND: Results from clinical trials examining the effect of intensive glucose control on cardiovascular disease have been conflicting. PURPOSE: To summarize clinical benefits and harms of intensive versus conventional glucose control for adults with type 2 diabetes. DATA SOURCES: Studies were retrieved by systematically searching the MEDLINE database (January 1950 to April 2009) with no language restrictions. STUDY SELECTION: Two independent reviewers screened abstracts or full-text articles to identify randomized trials that compared clinical outcomes in patients with type 2 diabetes receiving intensive glucose control and those receiving conventional glucose control. DATA EXTRACTION: Two investigators independently abstracted data on study variables and outcomes, including severe hypoglycemia, cardiovascular disease, and all-cause mortality. DATA SYNTHESIS: 5 trials involving 27,802 adults were included. Intensive glucose targets were lower in the 3 most recent trials. Summary analyses showed that compared with conventional control, intensive glucose control reduced the risk for cardiovascular disease (relative risk [RR], 0.90 [95% CI, 0.83 to 0.98]; risk difference per 1000 patients per 5 years [RD], -15 [CI, -24 to -5]) but not cardiovascular death (RR, 0.97 [CI, 0.76 to 1.24]; RD, -3 [CI, -14 to 7]) or all-cause mortality (RR, 0.98 [CI, 0.84 to 1.15]; RD, -4 [CI, -17 to 10]). Intensive glucose control increased the risk for severe hypoglycemia (RR, 2.03 [CI, 1.46 to 2.81]; RD, 39 [CI, 7 to 71]). As was seen in the overall analyses, pooled findings from the early and more recent trials showed that intensive glucose control reduced the risk for cardiovascular disease and increased the risk for severe hypoglycemia. LIMITATION: Summary rather than individual data were pooled across trials. CONCLUSION: Intensive glucose control reduced the risk for some cardiovascular disease outcomes (such as nonfatal myocardial infarction), did not reduce the risk for cardiovascular death or all-cause mortality, and increased the risk for severe hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A similar result was also found in another systematic review of the same data.450”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [450]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H. O. M., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,294
Research works printed but not linked: 2
- Shichiri M, 2000, Diabetes Care, 23, B21
- 10.1001/archinte.1997.00440230053007 · DOI
Cited by
Sorted by citations
Items 301–358 of 358
Molecular and psychosocial risk factors for cardiovascular disease
Rahman, I. (2013) · Figshare
Dapagliflozin for adults with type 2 diabetes mellitus
Raval, A. D., Chovatiya, K., Bhavsar, A. B., & Patel, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009001
Diabetes and Cardiovascular Mortality: From Epidemiologic Data to Clinical Trial Evidence
Chen, H.-S. (2010) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(10)70099-x
Prevención de los accidentes cerebrovasculares
Béjot, Y., Giroud, M., & Touzé, E. (2011) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(11)70970-9
Bloomgarden, Z. T. (2010) · Endocrine Practice · doi:10.4158/ep.16.s2.1
Factores de riesgo de complicaciones vasculares en extremidades inferiores en pacientes diabéticos
Monréal, M. (2010) · Medicina Clínica · doi:10.1016/j.medcli.2010.10.011
¿Es posible prevenir la nefropatía diabética? El estudio ROADMAP
Galcerán, J. (2011) · Hipertensión y Riesgo Vascular · doi:10.1016/s1889-1837(11)70003-4
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., EINHORN, D. F., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H. E., Levy, P. T., et al. (2009)
Chyun, D. A. (2010) · Evidence-Based Nursing · doi:10.1136/ebn.13.1.3
Lucas, E. G., Rey, V. R., Gutiérrez, J. M. Á., & García, J. J. L. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70433-x
CHIRURGINIS ANTRO TIPO CUKRINIO DIABETO GYDYMAS: EKONOMINIS ĮVERTINIMAS
Deduchovas, O. (2011) · Lithuanian University of Health Sciences
Medical management of risk factors for vascular disease
Morbi, A. H. M., & Shearman, C. P. (2015) · Surgery (Oxford) · doi:10.1016/j.mpsur.2015.04.007
Buitrago, F. (2010) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(10)70287-5
3. Glycemic Management of Type 2 Diabetes
D’Alessio, D. A., & Hirsch, I. B. (2011) · Translational endocrinology & metabolism · doi:10.1210/team.9781879225824.ch3
Grunberger, G., Abelseth, J. M., Bailey, T. S., Bode, B. W., Handelsman, Y., Hellman, R., Lane, W. S., Raskin, P., Tamborlane, W. V., & Rothermel, C. (2014)
Nemoto, N. (2015) · International Journal of Clinical Cardiology · doi:10.23937/2378-2951/1410020
“In fact, metaanalysis of recent trials involving intensive DM control revealed that this strategy decreased the risk of myocardial infarction and cardiovascular death [35].”
BackgroundBlauzdos arterijų endovaskulinių procedūrų ir šuntų į pėdos arteriją rezultatų analizė
Navickienė, A., Builytė, I. U., & Kalinauskas, G. (2015) · Lietuvos chirurgija · doi:10.15388/lietchirur.2015.3.8771
“This conclusion is supported by other studies where a strict glucose control was found to have effect only on patients with coronary artery disease [32, 33, 34].”
ResultGlucose Control in Type 2 Diabetes: Review of Cardiovascular Outcomes
Saitz, R., FACP., F., & Fasam (2009) · Journal watch · doi:10.1056/jw200911050000002
Aspirin in diabetes mellitus: mechanisms and clinical implications
Kurdee, Z. (2015) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
The Highs and Lows of Hemoglobin A1c
Lavis, V. R. (2016) · Cardiology · doi:10.1159/000444659
Sengupta, A. (2015) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Onuma, H., Takata, Y., & Osawa, H. (2013) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.44.429
Prévention des accidents vasculaires cérébraux
Béjot, Y., Giroud, M., & Touzé, E. (2010) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(10)53996-6
Advances in the study on metformin beyond its hypoglycemic effect
Yang, D., & Ye, S. (2013) · International Journal of Pathology and Clinical Medicine
Sluik, D. (2012) · doi:10.14279/depositonce-3267
“3) Food group intake, g/d Potatoes 85 [60-116] 102 [70-134] 74 [49-91] 83 [57-112] 99 [77-133] Vegetables 157 [129-192] 158 [130-194] 157 [129-191] 159 [132-195] 142 [114-171] Legumes 3 [0-7] 3 [0-7] 3 [0-6] 3 [0-7] 1 [0-5] Fruit 193 [133-281] 175 [116-274] 209 [153-284] 198 [137-287] 158 [111-221] Nuts and seeds 1 [0…”
Roseman, M., Lexchin, J., & Turner, E. H. (2017)
Sone, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99593-x
Oral diabetes treatments and cardiovascular disease
Saulnier, P., & Hadjadj, S. (2018) · doi:10.1093/med/9780198784906.003.0040_update_001
Épidémiologie des facteurs de risque de l'athérosclérose
Bongard, V. (2016) · Elsevier eBooks · doi:10.1016/b978-2-294-74970-4.00024-5
Fernández, M. A. (2018) · Medicina de Familia SEMERGEN · doi:10.1016/s1138-3593(18)30372-1
Ten things you should know about type 2 diabetes – part 2
Morris, D. (2019) · Independent Nurse · doi:10.12968/indn.2019.4.22
Liu, Y. (2018) · The Atrium (University of Guelph)
Targeting Multiple Risk Factors to Reduce Complications of Type 2 Diabetes: Treatment Imperatives
Palumbo, P. J. (2010) · Endocrine Practice · doi:10.1016/s1530-891x(20)42867-8
Sharma, M., Das, M., Sarma, J., & Alam, S. (2021) · The Indian Journal of Nutrition and Dietetics · doi:10.21048/ijnd.2021.58.2.26727
Wykrzykowska, J. J., & Renkens, M. P. L. (2021) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-021-02320-1
Siddiqui, N. A., Ishaque, I., Rahat, Y., Akhtar, N., Tehreem, U., Javed, R., & Ali, R. (2021) · ANNALS OF ABBASI SHAHEED HOSPITAL AND KARACHI MEDICAL & DENTAL COLLEGE · doi:10.58397/ashkmdc.v26i2.473
Risk factors and pharmacological therapy in patients with vascular disease
Maiolino, G., Rossato, M., & Vettor, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822113-6.00021-8
Individualisierte Behandlung: Jeder Diabetiker hat sein persönliches Therapieziel
Nauck, M. A. (2015) · Deutsches Ärzteblatt · doi:10.3238/persdia.2015.04.24.04
Yen, V. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_53
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00013-3
Medical management of risk factors for vascular disease
Pal, N., & Shearman, C. P. (2012) · Surgery (Oxford) · doi:10.1016/j.mpsur.2012.05.016
Codario, R. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-441-8_9
Type 2 Diabetes: Tight Control Does Not Affect Mortality
(2009) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)31154-8
Nahas, R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1793-8.00032-7
Correction: Glucose Control and Cardiovascular Disease in Type 2 Diabetes
(2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-1-201001050-00025
Control of Blood Glucose and Cardiovascular Risk Profile
Ciardullo, S., & Perseghin, G. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_28
Ramos, L. M. L. (2023) · Universidad Privada San Juan Bautista · doi:10.59590/upsjb/fcs.med.hum/tesis/4574
Fletcher‐Sanfeliu, D., Vidal, L., Enríquez, F., Tarrío, R. F., Padrol, D., Hidalgo, I., Velásquez, A. J., Rigo, M., Barril, R., & de Ibarra, J. I. S. (2024) · Cirugía Cardiovascular · doi:10.1016/j.circv.2023.10.002
Pleiotropic Effects of Renal Disease Management: Role of SGLT2 Inhibitors
Calderón-Lojero, I. O., Valdez-Ortiz, R., & Sanchez-Pozos, K. A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815305692125010018
Kézdi, Á., Horváth, V. J., Vass, V., Svébis, M. M., Kocsis, G., Ferencz, V., Jávorfí, T., Domján, B. A., & Tabák, Á. G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1690371
Effect of Glucose Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes
Lipska, K. J., & Inzucchi, S. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00010-0
Sone, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00162-x
An Update on the Top 100 Most-Cited Articles in Diabetes Research: A Bibliometric Analysis
Fahimi, R., Alrubayyi, A., Barber, T. M., & Uthman, O. A. (2026) · Data · doi:10.3390/data11080194
“It was the findings of the above trials that provided cardiovascular and renal benefit with new antidiabetic drugs that transitioned to practice [21].”
Bayer, F. J. (2011) · D-Scholarship@Pitt (University of Pittsburgh)
Metadata
- Authors
- Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., & He, J.
- Affiliations
- Tulane University (US)
- Corresponding author
- Kelly, Tanika N.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2009-09-15
- Volume
- 151
- Issue
- 6
- Pages
- 394-403
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC3058557
- OpenAlex
- W2166180770
- Cited by
- 358
- References
- 43
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 7 · 2021: 18 · 2020: 16 · 2019: 10 · 2018: 16 · 2017: 16 · 2016: 21 · 2015: 28 · 2014: 29 · 2013: 29 · 2012: 40
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (K08HL091108)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD043451)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic targets, cardiovascular disease, cardiovascular mortality, all-cause mortality, severe hypoglycemia, myocardial infarction, glycemic control
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Humans, Hypoglycemia, Hypoglycemic Agents, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
